-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Analysts said that under the background of the continuous expansion of medical needs caused by the aging process and the continuous improvement of people's consumption level, the trend of the pharmaceutical sector will continue to be optimistic
.
According to statistics, as of March 1, 2022, 243 A-share biopharmaceutical companies have released their 2021 performance forecasts.
According to the forecast, 160 listed pharmaceutical and biological companies will have "pre-happy" performance in 2021, accounting for more than 60%
.
Among them, 83 pharmaceutical companies are expected to increase their performance significantly, and the net profit of pharmaceutical companies such as Rejing Bio, Lisheng Pharmaceutical, and Ha Sanlian has increased by more than 1,000%
.
According to the 2021 annual performance report released by Rejing Bio on the evening of February 27, Rejing Bio achieved a year-on-year increase of 946.
14% in operating income in 2021 to 5.
372 billion yuan; net profit attributable to shareholders of the parent company increased by 1856.
81% year-on-year to 2.
193 billion yuan The non-net profit attributable to shareholders of the parent company was 2.
189 billion yuan, a year-on-year increase of 1878.
82%
.
Lisheng Pharmaceutical recently disclosed the 2021 annual performance report showing that the company will achieve a total operating income of 1.
092 billion yuan in 2021; the net profit attributable to shareholders of the listed company has increased by 1312.
60% year-on-year to 122 million yuan
.
Harbin Sanlian expects to achieve a year-on-year increase of 1090.
12%-1192.
42% in net profit attributable to the parent in 2021, about 349 million yuan to 379 million yuan
.
Among them, Lisheng Pharmaceutical stated that in the face of the impact of industry changes, the company has actively taken effective measures, strengthened budget management and cost control, and compressed various controllable expenses.
In 2021, both sales and management expenses have dropped significantly.
.
The company said that the company's performance has increased significantly, mainly due to the early 2021 company's antigen rapid detection reagent products, which were certified by the German Federal Institute for Drugs and Medical Devices (BfArM) for free home testing earlier, resulting in the first half of the year.
The explosive growth of foreign trade orders
.
In the second half of the year, the demand for antigen detection reagents in Europe, Southeast Asia and other countries and regions increased significantly, realizing a substantial increase in overseas detection reagent revenue
.
However, at the same time, Rejing Bio also pointed out that whether the company's future sales performance can continue to maintain a trend of substantial growth, there is a certain uncertainty, depending on the progress of global epidemic prevention and control, the international epidemic's path selection for technology products, and the company's products.
Market competitiveness and channel capability
.
It is understood that in addition to Rejing Bio, there is also a strong overseas demand for products such as testing kits from companies such as Jiu'an Medical, Yirui Bio, Mingde Bio, and Oriental Bio
.
Analysts said that the rigid demand attribute of the pharmaceutical sector is unchanged compared to the certainty of growth in other industries
.
In the context of the continuous increase in the penetration rate of just-needed medicine expansion and health consumption upgrades brought about by the aging process, it remains optimistic about the medium and long-term trend of the pharmaceutical sector
.
In addition, with the help of policies, the biopharmaceutical industry will also usher in more development opportunities
.
For example, when the "13th Five-Year Plan" ended and the "14th Five-Year Plan" started, various provinces and cities mentioned the biopharmaceutical industry many times, and included biomedicine in the "14th Five-Year Plan" special plan to further guide enterprises to break through core technologies and rely on major science and technology.
Special projects and special projects for high-quality development of the manufacturing industry will strengthen key core technologies and product research, strengthen international cooperation in the field of technology, effectively and effectively solve the "stuck neck" problem, and provide strong support for building a modern economic system and achieving high-quality economic development
.
According to industry forecasts, driven by favorable policies, China's biopharmaceutical industry will have a broad market space.
It is estimated that by 2025, China's biopharmaceutical market will reach 831 billion yuan
.
.
According to statistics, as of March 1, 2022, 243 A-share biopharmaceutical companies have released their 2021 performance forecasts.
According to the forecast, 160 listed pharmaceutical and biological companies will have "pre-happy" performance in 2021, accounting for more than 60%
.
Among them, 83 pharmaceutical companies are expected to increase their performance significantly, and the net profit of pharmaceutical companies such as Rejing Bio, Lisheng Pharmaceutical, and Ha Sanlian has increased by more than 1,000%
.
According to the 2021 annual performance report released by Rejing Bio on the evening of February 27, Rejing Bio achieved a year-on-year increase of 946.
14% in operating income in 2021 to 5.
372 billion yuan; net profit attributable to shareholders of the parent company increased by 1856.
81% year-on-year to 2.
193 billion yuan The non-net profit attributable to shareholders of the parent company was 2.
189 billion yuan, a year-on-year increase of 1878.
82%
.
Lisheng Pharmaceutical recently disclosed the 2021 annual performance report showing that the company will achieve a total operating income of 1.
092 billion yuan in 2021; the net profit attributable to shareholders of the listed company has increased by 1312.
60% year-on-year to 122 million yuan
.
Harbin Sanlian expects to achieve a year-on-year increase of 1090.
12%-1192.
42% in net profit attributable to the parent in 2021, about 349 million yuan to 379 million yuan
.
Among them, Lisheng Pharmaceutical stated that in the face of the impact of industry changes, the company has actively taken effective measures, strengthened budget management and cost control, and compressed various controllable expenses.
In 2021, both sales and management expenses have dropped significantly.
.
The company said that the company's performance has increased significantly, mainly due to the early 2021 company's antigen rapid detection reagent products, which were certified by the German Federal Institute for Drugs and Medical Devices (BfArM) for free home testing earlier, resulting in the first half of the year.
The explosive growth of foreign trade orders
.
In the second half of the year, the demand for antigen detection reagents in Europe, Southeast Asia and other countries and regions increased significantly, realizing a substantial increase in overseas detection reagent revenue
.
However, at the same time, Rejing Bio also pointed out that whether the company's future sales performance can continue to maintain a trend of substantial growth, there is a certain uncertainty, depending on the progress of global epidemic prevention and control, the international epidemic's path selection for technology products, and the company's products.
Market competitiveness and channel capability
.
It is understood that in addition to Rejing Bio, there is also a strong overseas demand for products such as testing kits from companies such as Jiu'an Medical, Yirui Bio, Mingde Bio, and Oriental Bio
.
Analysts said that the rigid demand attribute of the pharmaceutical sector is unchanged compared to the certainty of growth in other industries
.
In the context of the continuous increase in the penetration rate of just-needed medicine expansion and health consumption upgrades brought about by the aging process, it remains optimistic about the medium and long-term trend of the pharmaceutical sector
.
In addition, with the help of policies, the biopharmaceutical industry will also usher in more development opportunities
.
For example, when the "13th Five-Year Plan" ended and the "14th Five-Year Plan" started, various provinces and cities mentioned the biopharmaceutical industry many times, and included biomedicine in the "14th Five-Year Plan" special plan to further guide enterprises to break through core technologies and rely on major science and technology.
Special projects and special projects for high-quality development of the manufacturing industry will strengthen key core technologies and product research, strengthen international cooperation in the field of technology, effectively and effectively solve the "stuck neck" problem, and provide strong support for building a modern economic system and achieving high-quality economic development
.
According to industry forecasts, driven by favorable policies, China's biopharmaceutical industry will have a broad market space.
It is estimated that by 2025, China's biopharmaceutical market will reach 831 billion yuan
.
